Skip to Content

Novartis AG ADR NVS

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Novartis’ R&D Day Highlights Solid Drug Portfolio, Reinforcing the Firm’s Wide Moat

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Novartis’ research and development investor day highlighted a strong drug portfolio that enforces our confidence in the firm’s wide moat. While some additional positive datapoints were highlighted, we are not making any major fair value estimate changes based on the update. We continue to view the company as undervalued with the market not fully appreciating the firm’s current portfolio and developing pipeline.

Read Full Analysis

Company Profile

Business Description

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.

Contact
Lichtstrasse 35
Basel, 4056, Switzerland
T +41 613241111
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 109,000

Related